Ablynx’s Partner, Merck KGaA, Has Presented New Data from a Phase Ib…

GHENT, Belgium, 6 March 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA , has presented new data from a Phase Ib study demonstrating strong efficacy with the bi-specific anti-IL-17A/F Nanobody® in patients with moderate-to-severe chronic plaque psoriasis. The results were presented at the 75th Annual Meeting of the American Academy of Dermatology Conference, taking place from 3-7 March 2017, in Orlando, Florida.

Psoriasis Treatment Market Precise Industry Analysis and Growth…

The global market for psoriasis treatment demonstrates a highly competitive landscape, especially due to the rising investments in the field of psoriasis treatment connected to research and development as stated in the latest report from Transparency Market Research. This study has been recently added to the wide portfolio of Market Research Hub’s research studies.

How Big Is the Opportunity for Celgene’s Otezla Overseas?

Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.

Successful psoriasis treatment

Americans spend over $71 billion a year on lottery tickets – and scratch-off games are a huge favorite. But that’s nothing compared with the $112 billion that’s spent annually to deal with the itchy skin condition psoriasis and its associated health problems, such as arthritis, depression and cardiovascular disease.

Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships

Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, would like to wish all Cellceutix shareholders, their families and friends a happy and healthy holiday season. In 2016, Cellceutix remained extremely transparent in keeping shareholders current on developments, including comprehensive updates via news releases and corporate presentations covering the status of clinical trials and anticipated milestones pertaining to those trials for 2017.